Bromocriptine in the treatment of post-polio fatigue: A pilot study with implications for the pathophysiology of fatigue

American Journal of Physical Medicine and Rehabilitation

Volumn 75, Issue 5, 1996, Pages 340-347

  Bruno, Richard L ^a,b   Zimmerman, Jerald R ^a,b   Creange, Susan J ^a   Lewis, Todd ^a   Molzen, Terry ^a   Frick, Nancy M ^c  

^a KESSLER INSTITUTE FOR REHABILITATION   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c Harvest Center   (United States)

Author keywords

Attention; Bromocriptine; Dopamine; Fatigue; Polio; Post Polio Sequelae

Indexed keywords

BRAIN; COMPOSITION EFFECTS; DISEASES; DRUG PRODUCTS; DRUG THERAPY; MAGNETIC RESONANCE IMAGING; NEUROPHYSIOLOGY; PSYCHOPHYSIOLOGY;

BROMOCRIPTINE MESYLATE; DOPAMINE; PATHOPHYSIOLOGY; PLACEBO; POST POLIO FATIGUE; POST POLIO SEQUELAE;

HUMAN REHABILITATION ENGINEERING;

BROMOCRIPTINE MESILATE; CORTICOTROPIN; PLACEBO; PROLACTIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FATIGUE; FEMALE; HEADACHE; HUMAN; MALE; NAUSEA; NEUROPSYCHOLOGICAL TEST; NOSE CONGESTION; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; POSTPOLIOMYELITIS SYNDROME; SYMPTOMATOLOGY;

ADRENOCORTICOTROPIC HORMONE; BROMOCRIPTINE; DOPAMINE AGONISTS; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; POSTPOLIOMYELITIS SYNDROME; PSYCHOLOGICAL TESTS;

EID: 0030249719     PISSN: 08949115     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002060-199609000-00007     Document Type: Article

References (39)

1. Parsons PE: National Health Interview Survey. Hyattsville, MD, National Center for Health Statistics, 1989.
2. Bruno RL, Frick NM: Stress and "type A" behavior as precipitants of post-polio sequelae, in Halstead LS, Wiechers DO (eds): Research and Clinical Aspects of the Late Effects of Poliomyelitis. White Plains, NY, March of Dimes Research Foundation, 1987, pp 145-155.
3. Bruno RL, Frick NM, Cohen, J: Polioencephalitis, stress and the etiology of post-polio sequelae. Orthopedics 1991;14: 1269-1276.
4. Bruno RL, Galski T, DeLuca J: The neuropsychology of post-polio fatigue. Arch Phys Med Rehabil 1993;74:1061-1065.
5. Bodian D: Histopathological basis of clinical findings in poliomyelitis. Am J Med 1949;6:563-578.
6. Bruno RL, Cohen J, Galski T, Frick NM: The neuroanatomy of post-polio fatigue. Arch Phys Med Rehabil 1994;74:1061-1065.
7. Bruno RL, Sapolsky R, Zimmerman JR, Frick NM: The pathophysiology of a central cause of post-polio fatigue. Ann NY Acad Sci 1995;753:257-275.
8. Bruno RL, Frick NM: The psychology of polio as prelude to post-polio sequelae: behavior modification and psychotherapy. Orthopedics 1991;14:1185-1193.
9. Agre JC, Rodriguez AA: Neuromuscular function in polio survivors. Orthopedics 1991;14:1343-1347.
10. Young GR: Energy conservation, occupational therapy and the treatment of post-polio sequelae. Orthopedics 1991;14: 1233-1239.
11. Diagnostic, and Statistical Manual III, Revised. New York, American Psychiatric Association, 1995.
12. Lezak MD: Neuropsychological Assessment. New York, Oxford University Press, 1976.
13. Gordon M: Microprocessor-based assessment of attention deficit disorders (ADD). Psychopharmacol Bull 1986;22:288-290.
14. Reitan RM: The Halstead-Reitan Neuropsychological Battery: Theory and Clinical Practice. Tucson, Neuropsychology Press, 1985.
15. Gronwall DMA: The paced auditory serial-addition task: a measure of recovery from concussion. Percept Motor Skills 1977;44: 367-373.
16. Wilkinson L, Hill M: SYSTAT (Version 6.0). Chicago, SPSS, 1995.
17. Guilford JP, Fruchter B: Fundamental Statistics in Psychology and Education. New York, McGraw-Hill, 1973.
18. Pagan D, Scott DD, Mitchell M, Tiplady B: Effects of remoxipride on measures of psychological performance in healthy volunteers. Psychopharmacology 1991;105:225-229.
19. Dinsmore S, Dambrosia J, Dalakas MC: A double-blind, placebo-controlled trial of high-dose prednisone for the treatment of post-poliomyelitis syndrome. Ann NY Acad Sci 1995;753: 303-313.
20. Stein DP, Dambrosia JM, Dalakas MC: A double-blind, placebo-controlled trial of amantadine for the treatment of fatigue in patients with the post-polio syndrome. Ann NY Acad Sci 1995;753:296-302.
21. Trojan DA, Cashman NR: An open trial of pyridostigmine in post-poliomyelitis syndrome. Can J Neurol Sci 1995;22:223-227.
22. Kleitman N: Sleep and Wakefulness. Chicago, University of Chicago Press, 1939.
23. Gellhorn E: The influence of curare on hypothalamic excitability and the electroencephalogram. EEG Clin Neurophysiol 1958;10:697-703.
24. Hodes R: Electrocortical synchronization resulting from reduced proprioceptive drive caused by neuromuscular blocking agents. EEG Clin Neurophysiol 1962;14:220-232.
25. Shea LT, Davidson GM, Davis J: Electroencephalographic studies of the curarized patient. Med J Aust 1954;2:656-659.
26. Edwards RHT: Human muscle function and fatigue, in Ciba Foundation Symposium 82: Human Muscle Fatigue. Pittman, London, 1981.
27. Bruno RL, Frick NM, Creange S, Zimmerman JR, Lewis T: Polioencephalitis and the Brain Fatigue Generator model of post-viral fatigue syndromes. J Chronic Fatigue Syndrome 1996;2: 5-27.
28. Bruno RL: Predicting hyperactive behavior as a cause of non-compliance with rehabilitation: the reinforcement motivation survey. J Rehabil 1995;61:50-57.
29. Quinn A, Ilas A, Lherrmitte F, Agid Y: Bromocriptine and domperidone in the treatment of Parkinson's disease. Neurology 1981;31:662-667.
30. Baker AB: Neurologic signs of bulbar poliomyelitis, in Poliomyelitis. Philadelphia, JB Lippincott, 1949.
31. Bruno RL, Frick NM: Parasympathetic abnormalities as post-polio sequelae. Arch Phys Med Rehabil 1995;76:594.
32. Bruno RL, Frick NM, Creange SJ: Nocturnal generalized myoclonus as a post-polio sequelae. Arch Phys Med Rehabil 1995;76:594.
33. Lee TH, Ellinwood EH, Nishita JK: Dopamine receptor sensitivity changes with chronic stimulants. Ann NY Acad Sci 1988;537:324-329.
34. Kartzinel R, Calne DB: Studies with bromocriptine: I. "On-off" phenomena. Neurology 1976;26:508-510.
35. Lees AJ, Haddad S, Shaw KM, et al.: Bromocriptine in parkinsonism a long-term study. Arch Neurol 1978;35:503-505.
36. Wong DF, Wagner HN, Dannals RF, et al.: Effects of age on dopamine and serotonin receptors measured by positron emission tomography in the living human brain. Science 1984;226:1393-1396.
37. 11C-Raclopride. Arch Neurol 1993; 50:474-480.
38. Jenner P: The rationale for the use of dopamine agonists for Parkinson's disease. Neurology 1995;45(suppl 3):S6-S12.
39. Yoshikawa T, Minamiyama Y, Naito Y, Motoharu K: Antioxidant properties of Bromocriptine, a dopamine agonist. J Neurochem 1994;62:1034-1038.